2023

1. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

   Leukemia, Vol. 37, Núm. 7, pp. 1521-1529